Component: (Network and Table)
Network
00500 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS
(http://www.glaukos.com/role/StatementConsolidatedStatementsOfCashFlows)
TableStatement [Table]
Slicers (applies to each fact value in each table cell)
Reporting Entity [Axis]0001192448 (http://www.sec.gov/CIK)
Equity Components [Axis]Equity Component [Domain]
StatementPeriod [Axis]
2016-01-01 - 2016-12-31
2015-01-01 - 2015-12-31
2014-01-01 - 2014-12-31
Operating Activities
 
 
 
Net income (loss)
4,522,000  
(38,321,000) 
(14,057,000) 
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
 
 
 
Depreciation and amortization
4,722,000  
4,267,000  
4,231,000  
Loss on disposal of fixed assets
40,000  
  
Stock-based compensation
8,786,000  
7,889,000  
1,530,000  
Loss on deconsolidation of DOSE
 
25,685,000  
 
Loss on extinguishment of debt
 
186,000  
 
Change in fair value of stock warrant liability
(43,000) 
1,132,000  
(5,000) 
Unrealized foreign currency losses
368,000  
192,000  
 
Amortization of premium on short-term investments
210,000  
51,000  
 
Amortization of debt discount and deferred financing costs
 
15,000  
 
Deferred rent
(31,000) 
91,000  
(33,000) 
Change in operating assets and liabilities:
 
 
 
Accounts receivable, net
(6,791,000) 
(2,163,000) 
(2,514,000) 
Inventory
(2,935,000) 
(1,848,000) 
(413,000) 
Prepaid expenses and other current assets
(1,762,000) 
(755,000) 
(108,000) 
Accounts payable and accrued liabilities
5,096,000  
1,518,000  
4,226,000  
Other assets
127,000  
(127,000) 
36,000  
Net cash provided by (used in) operating activities
12,309,000  
 
(2,188,000) 
 
(7,107,000) 
 
Investing activities
 
 
 
Purchases of property and equipment
(6,278,000) 
(877,000) 
(868,000) 
Purchase of iDOSE product line and related assets from DOSE Medical
 
(15,000,000) 
 
Purchases of short-term investments
(75,192,000) 
(69,751,000) 
 
Proceeds from sale and maturities of short-term investments
55,354,000  
  
Net cash used in investing activities
(26,116,000) 
 
(85,628,000) 
 
(868,000) 
 
Financing activities
 
 
 
Proceeds from public offering, net of issuance costs
 
113,589,000  
 
Proceeds from senior secured term and draw-to term loans
 
6,852,000  
 
Payments of senior secured term and draw-to term loans
 
(7,000,000) 
 
Proceeds from line of credit
 
1,750,000  
2,850,000  
Payments of line of credit
 
(3,600,000) 
(1,000,000) 
Payments of subordinated notes
(9,696,000) 
(7,804,000) 
 
Proceeds from exercise of stock options
6,059,000  
1,734,000  
775,000  
Share purchases under Employee Stock Purchase Plan
1,945,000  
1,161,000  
 
Proceeds from exercise of stock warrants
50,000  
428,000  
875,000  
Net cash (used in) provided by financing activities
(1,642,000) 
 
107,110,000  
 
3,500,000  
 
Effect of exchange rate changes on cash and cash equivalents
371,000  
(26,000) 
51,000  
Net (decrease) increase in cash and cash equivalents
(15,078,000) 
 
19,268,000  
 
(4,424,000) 
 
Cash and cash equivalents at beginning of period
21,572,000  
2,304,000  
6,728,000  
Cash and cash equivalents at end of period
6,494,000  
 
21,572,000  
 
2,304,000  
 
Supplemental disclosures of cash flow information
 
 
 
Interest paid
285,000  
834,000  
876,000  
Taxes paid, net of refunds
513,000  
25,000  
12,000  
Supplemental schedule of noncash investing and financing activities
 
 
 
Purchase of intangible assets in exchange for future payments
 
243,000  
 
Conversion of preferred stock into common stock
 
159,077,000  
 
Reduction of liability upon vesting of stock options previously exercised for unvested stock
62,000  
86,000  
80,000